ARQL ArQule, Inc.

1.20
-0.27  -18.37%
Previous Close 1.47
Open 1.25
Price To book 3.48
Market Cap 85.34M
Shares 71,118,000
Volume 2,450,163
Short Ratio 3.99
Av. Daily Volume 145,208

NewsSee all news

  1. ArQule Liver Cancer Drug Fails Phase 3 Trial
  2. ArQule, Inc. (ARQL)’s Liver Cancer Drug Fails: What’s Next?
  3. 6:02 am ArQule and Daiichi Sankyo (DSNKY) announce the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma did not meet its primary endpoint of improving overall survival
  4. Sabre Corp., L Brands Dip into Friday’s 52-Week Low Club
  5. ARQULE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment to be completed soon - as of November 2016.
ARQ 087
intrahepatic cholangiocarcinoma (iCCA)
Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
Tivantinib (ARQ 197) METIV-HCC trial
Previously treated Inoperable Hepatocellular Carcinoma cancer

Latest News

  1. ArQule Liver Cancer Drug Fails Phase 3 Trial
  2. ArQule, Inc. (ARQL)’s Liver Cancer Drug Fails: What’s Next?
  3. 6:02 am ArQule and Daiichi Sankyo (DSNKY) announce the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma did not meet its primary endpoint of improving overall survival
  4. Sabre Corp., L Brands Dip into Friday’s 52-Week Low Club
  5. ARQULE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  6. Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma
  7. Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma
  8. Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma
  9. ArQule to Present at The Leerink Partners 6th Annual Global Healthcare Conference on February 15, 2017
  10. ArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher
  11. ARQULE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
  12. ETFs with exposure to ArQule, Inc. : December 21, 2016
  13. How ArQule, Inc. (ARQL) Stacks Up Against Its Peers
  14. Data on Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition of Wild Type and C481S Mutant BTK and Superiority to Ibrutinib in TCL1 Mouse Model Presented at the American Society of Hematology Annual Meeting
  15. Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting
  16. ARQULE INC Financials
  17. Could Trump Tax Cut Plans, Republican Congress Spur Biotech M&A?
  18. ArQule, Inc. :ARQL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 8, 2016
  19. Edited Transcript of ARQL earnings conference call or presentation 7-Nov-16 2:00pm GMT
  20. ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits